1.	EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Phase: Phase IV Type: Treatment Status: Approved-not yet active Age: 6 months to 21 years Sponsor: Other Protocol IDs: SHEBA-06-4013-IK-CTIL, NCT00339118
2.	A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and under Sponsor: NICHD Protocol IDs: PPRU 10762, NCT00491946
3.	Reduced Intensity Transplant Using Extracorporeal Photopheresis Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and under Sponsor: Pharmaceutical / Industry Protocol IDs: ECP RIT, NCT00179790
4.	A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 12 to 17 Sponsor: Pharmaceutical / Industry Protocol IDs: CLDE225X2104, 2010-019348-37, NCT01125800
5.	New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma Phase: Phase II, Phase I Type: Treatment Status: Approved-not yet active Age: 3 to 75 Sponsor: Other Protocol IDs: NDV-HUJ-HMO-CTIL, NCT01174537
6.	To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 20 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: 100220, IND 59,056, NCT01222780
7.	Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 4 to 21 Sponsor: Other Protocol IDs: 10-096, NCT01294670
8.	Aerosol IL-2 for Pulmonary Metastases Phase: Phase II, Phase I Type: Treatment Status: Active Age: 12 and over Sponsor: Other Protocol IDs: 2010-0700, NCT01590069
9.	Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: PSCI-2003-232, NCT00084695
10.	Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 (rIL-2) for Metastatic Solid Tumors Phase: Phase II Type: Treatment Status: Active Age: Under 70 Sponsor: Other Protocol IDs: 271296-HMO-CTIL, NCT00149006
11.	Radiation Therapy to Treat Musculoskeletal Tumors Phase: Phase II Type: Treatment Status: Active Age: 25 and under Sponsor: Other Protocol IDs: RTSARC, NCT00186992
12.	Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse Phase: Phase II Type: Treatment Status: Active Age: 1 to 25 Sponsor: Other Protocol IDs: NAVE-CYCLO, NCT00180947
13.	Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: 05-122, MSKCC-05122, NCT00445965
14.	Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors Phase: Phase II Type: Treatment Status: Active Age: 12 to 70 Sponsor: Other Protocol IDs: 0457-08-HMO-CTIL, NCT00855452
15.	Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours Phase: Phase II Type: Treatment Status: Active Age: 6 months to 20 years Sponsor: Other Protocol IDs: CSET 2008/1378, NCT00918320
16.	MLN8237 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 21 Sponsor: NCI, Other Protocol IDs: CDR0000680512, COG-ADVL0921, ADVL0921, NCT01154816
17.	Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas Phase: Phase II Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: CRAD001CBR08T, NCT01216839
18.	Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma Phase: Phase II Type: Treatment Status: Active Age: Under 30 Sponsor: NCI Protocol IDs: NCI-2011-02607, ARST0921, CDR0000687113, U10CA098543, COG-ARST0921, NCT01222715
19.	Vincristine and Irinotecan With or Without Temozolomide in Children and Adults With Refractory or Relapsed Rhabdomyosarcoma : International Randomized Trial Phase: Phase II Type: Treatment Status: Active Age: 6 months to 50 years Sponsor: Other Protocol IDs: VIT-0910, NCT01355445
20.	Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas. Phase: Phase II Type: Diagnostic, Treatment Status: Active Age: 5 to 49 Sponsor: Other Protocol IDs: NCCCTS-08-322, NCT01380275
21.	Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 30 Sponsor: NCI Protocol IDs: NCI-2012-00106, ADVL1121, U10CA098543, CDR0000721611, COG-ADVL1121, NCT01502410
22.	CREATE: Cross-tumoral Phase 2 With Crizotinib Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 15 and over Sponsor: Other Protocol IDs: EORTC-90101, 2011-001988-52, NCT01524926
23.	Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 15 and over Sponsor: Other Protocol IDs: SOL-11130-L, NCI-2012-00052, IRB# 7943, NCT01532687
24.	A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors Phase: Phase II Type: Treatment Status: Active Age: 0 to 40 Sponsor: Other Protocol IDs: J12106, NCT01804634
25.	Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors Phase: Phase II Type: Treatment Status: Approved-not yet active Age: Under 21 Sponsor: Other Protocol IDs: CR0113061, NCT01807468